HomeCompareVWIUX vs MRK

VWIUX vs MRK: Dividend Comparison 2026

VWIUX yields 3.05% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $32.5K in total portfolio value
10 years
VWIUX
VWIUX
● Live price
3.05%
Share price
$13.66
Annual div
$0.42
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.3K
Annual income
$371.67
Full VWIUX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — VWIUX vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVWIUXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VWIUX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VWIUX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VWIUX
Annual income on $10K today (after 15% tax)
$259.51/yr
After 10yr DRIP, annual income (after tax)
$315.92/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,012.49/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VWIUX + MRK for your $10,000?

VWIUX: 50%MRK: 50%
100% MRK50/50100% VWIUX
Portfolio after 10yr
$40.5K
Annual income
$5,084.90/yr
Blended yield
12.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

VWIUX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VWIUX buys
0
MRK buys
0
No recent congressional trades found for VWIUX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVWIUXMRK
Forward yield3.05%2.76%
Annual dividend / share$0.42$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$24.3K$56.8K
Annual income after 10y$371.67$9,798.13
Total dividends collected$3.4K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VWIUX vs MRK ($10,000, DRIP)

YearVWIUX PortfolioVWIUX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$11,005$305.31$11,206$366.19$201.00MRK
2$12,090$314.02$12,650$502.35$560.00MRK
3$13,258$322.39$14,407$694.19$1.1KMRK
4$14,517$330.43$16,585$967.82$2.1KMRK
5$15,871$338.12$19,342$1,363.89$3.5KMRK
6$17,328$345.48$22,913$1,947.19$5.6KMRK
7$18,893$352.51$27,662$2,823.89$8.8KMRK
8$20,575$359.21$34,159$4,173.35$13.6KMRK
9$22,381$365.60$43,337$6,308.80$21.0KMRK
10$24,319$371.67$56,776$9,798.13$32.5KMRK

VWIUX vs MRK: Complete Analysis 2026

VWIUXStock

The fund’s investment objective is to seek to provide a moderate and sustainable level of current income that is exempt from federal personal income taxes. The fund has no limitations on the maturity of individual securities but is expected to maintain a dollar-weighted average maturity of 6 to 12 years. At least 75% of the securities held by the fund are municipal bonds in the top three credit-rating categories as determined by a nationally recognized statistical rating organization or, if unrated, determined to be of comparable quality by the advisor. The fund may invest up to 20% of its assets in medium-grade bonds, as determined by a rating organization or by the advisor. The remaining 5% may be invested in securities with lower credit ratings or, if unrated, determined to be of comparable quality by the advisor. Risks of the fund include the fact that changes in interest rates, both up and down, can affect the fund by resulting in lower bond prices or an eventual decrease in income for the fund. Investors who are looking for a fund that may provide federal tax-exempt interest income and can tolerate moderate price and income fluctuations may wish to consider this fund.The Vanguard Intermediate-Term Tax-Exempt Fund is a stand alone product and is separate and distinct from the Vanguard Intermediate-Term Tax-Exempt Bond ETF (VTEI). Differences in scale, certain investment processes, and underlying holdings are expected to produce different investment returns by the funds.

Full VWIUX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this VWIUX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VWIUX vs SCHDVWIUX vs JEPIVWIUX vs OVWIUX vs KOVWIUX vs MAINVWIUX vs JNJVWIUX vs ABBVVWIUX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.